CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30 - Área de Salud Badajoz

Ir al contenido principal

Av. de Huelva, 8. 06005 Badajoz

info@areasaludbadajoz.com

info@areasaludbadajoz.com

Guía telefónica
Área de Salud

Inicio Repositorio CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30

2013

CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment. Pharmacogenet Genomics. 2013 Nov;23(11):627-30

Autores/as:

Almoguera B, Riveiro-Alvarez R, Lopez-Castroman J, Dorado P, Vaquero-Lorenzo C, Fernandez-Piqueras J, Llerena A, Abad-Santos F, Baca-García E, Dal-Ré R, Ayuso C; Spanish Consortium of Pharmacogenetics Research in Schizophrenia

Servicio:

CICAB

Tipo:

Artículo

Materia:

Citocromo P-450 CYP2D6

{«label»:»Resumen PubMed»,»link»:»http://www.ncbi.nlm.nih.gov/pubmed/?term=24026091″}